Ausgabe 4/2014
Inhalt (13 Artikel)
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
Jeffrey L Cummings, Travis Morstorf, Kate Zhong
Basic to translational research in dementia: meeting report from the Alzheimer’s Research UK Conference 2014
Rosa M Sancho, Simon H Ridley, Laura E Phipps, Eric Karran
Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer’s disease immunotherapeutics
William F Goure, Grant A Krafft, Jasna Jerecic, Franz Hefti
Cerebral inflammation is an underlying mechanism of early death in Alzheimer’s disease: a 13-year cause-specific multivariate mortality study
Katarina Nägga, Carina Wattmo, Yi Zhang, Lars-Olof Wahlund, Sebastian Palmqvist
Differentially charged isoforms of apolipoprotein E from human blood are potential biomarkers of Alzheimer’s disease
Oscar Alzate, Cristina Osorio, Robert M DeKroon, Ana Corcimaru, Harsha P Gunawardena
The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis
Paul C Donaghy, Ian G McKeith
Imaging as a biomarker in drug discovery for Alzheimer’s disease: is MRI a suitable technology?
Emilio Merlo Pich, Andreas Jeromin, Giovanni B Frisoni, Derek Hill, Andrew Lockhart, Mark E Schmidt, Martin R Turner, Stefania Mondello, William Z Potter
Association of MAPT haplotypes with Alzheimer’s disease risk and MAPT brain gene expression levels
Mariet Allen, Michaela Kachadoorian, Zachary Quicksall, Fanggeng Zou, High Seng Chai, Curtis Younkin, Julia E Crook, V Shane Pankratz, Minerva M Carrasquillo, Siddharth Krishnan, Thuy Nguyen, Li Ma, Kimberly Malphrus, Sarah Lincoln, Gina Bisceglio, Christopher P Kolbert, Jin Jen, Shubhabrata Mukherjee, John K Kauwe, Paul K Crane, Jonathan L Haines, Richard Mayeux, Margaret A Pericak-Vance, Lindsay A Farrer, Gerard D Schellenberg, Joseph E Parisi, Ronald C Petersen, Neill R Graff-Radford, Dennis W Dickson, Steven G Younkin, Nilüfer Ertekin-Taner
The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial
Niels D Prins, Wiesje A van der Flier, Dirk L Knol, Nick C Fox, H Robert Brashear, Jeffrey S Nye, Frederik Barkhof, Philip Scheltens
Subcortical hyperintensity volumetrics in Alzheimer’s disease and normal elderly in the Sunnybrook Dementia Study: correlations with atrophy, executive function, mental processing speed, and verbal memory
Joel Ramirez, Alicia A McNeely, Christopher JM Scott, Donald T Stuss, Sandra E Black
Treatment effects in multiple cognitive domains in Alzheimer’s disease: a two-year cohort study
Pearl Behl, Jodi D Edwards, Alexander Kiss, Krista L Lanctot, David L Streiner, Sandra E Black, Donald T Stuss
Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Rostislav Skrabana, Michal Novak
First-in-man tau vaccine targeting structural determinants essential for pathological tau–tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer’s disease model
Eva Kontsekova, Norbert Zilka, Branislav Kovacech, Petr Novak, Michal Novak